ReviewAdvances in experimental medicine and biology2020
Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment.
Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 25 citations in OpenAlex.
- The crosstalk between lymphatic endothelial cells and immune cells in Physiological and Pathological conditions.Cellular and molecular life sciences : CMLS · 2026Review
- Beyond Drainage: How Lymphatic Vessels Instruct Immune Cell Fate.Journal of inflammation research · 2026Review
- Exosomal regulation of cellular reprogramming and polarization in the tumor microenvironment.Cancer cell international · 2025Review
- Bone Marrow Myeloid-Lymphatic Progenitors Expand Tumor Lymphatic Vasculature Through Cell Fusion.Cancers · 2025Article
- Molecular and Cellular Machinery of Lymphatic Metastasis in Breast Cancer.OncoTargets and therapy · 2025Review
- Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations.Frontiers in immunology · 2025Article
- Cell-cell contact-dependent secretion of large-extracellular vesicles from EFNBBritish journal of cancer · 2024Article
- The global landscape and research trend of lymphangiogenesis in breast cancer: a bibliometric analysis and visualization.Frontiers in oncology · 2024Review
- Tumor microenvironment restricts IL-10 induced multipotent progenitors to myeloid-lymphatic phenotype.PloS one · 2024Article
- Fibrinogen-to-albumin ratios are related to mortality in patients with secondary malignant neoplasm of bone and bone marrow.Heliyon · 2023Article
- Interaction of tumor‑associated macrophages with stromal and immune components in solid tumors: Research progress (Review).International journal of oncology · 2023Review
- CD34 positive cells as endothelial progenitor cells in biology and medicine.Frontiers in cell and developmental biology · 2023Review
- Review
- Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.Molecular and cellular biochemistry · 2022Review
- Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.Stem cells and development · 2022Article
- Neuroinflammation creates an immune regulatory niche at the meningeal lymphatic vasculature near the cribriform plate.Nature immunology · 2022Article
- Distinctive Roles of YAP and TAZ in Human Endothelial Progenitor Cells Growth and Functions.Biomedicines · 2022Article
- Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.World journal of gastroenterology · 2021Review
- Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression.Cancer metastasis reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Tumor lymphatics play a key role in cancer progression as they are solely responsible for transporting malignant cells to regional lymph nodes (LNs), a process that precedes and promotes systemic lethal spread. It is broadly accepted that tumor lymphatic sprouting is induced mainly by soluble factors derived from tumor-associated macrophages (TAMs) and malignant cells. However, emerging evidence strongly suggests that a subset of TAMs, myeloid-lymphatic endothelial cell progenitors (M-LECP), also contribute to the expansion of lymphatics through both secretion of paracrine factors and a self-autonomous mode. M-LECP are derived from bone marrow (BM) precursors of the monocyte-macrophage lineage and characterized by unique co-expression of markers identifying lymphatic endothelial cells (LEC), stem cells, M2-type macrophages, and myeloid-derived immunosuppressive cells. This review describes current evidence for the origin of M-LECP in the bone marrow, their recruitment tumors and intratumoral trafficking, similarities to other TAM subsets, and mechanisms promoting tumor lymphatics. We also describe M-LECP integration into preexisting lymphatic vessels and discuss potential mechanisms and significance of this event. We conclude that improved mechanistic understanding of M-LECP functions within the tumor environment may lead to new therapeutic approaches to suppress tumor lymphangiogenesis and metastasis to lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.